Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Should You Buy?

Shares of Citius Oncology, Inc. (NASDAQ:CTOR) were up 39.8% on Monday . The stock traded as high as $1.17 and last traded at $0.93. Approximately 70,080,356 shares were traded during mid-day trading, an increase of 5,249% from the average daily volume of 1,310,223 shares. The stock had previously closed at $0.67.

Citius Oncology Stock Down 7.0 %

The company has a quick ratio of 0.08, a current ratio of 0.34 and a debt-to-equity ratio of 0.08. The stock’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.14.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings results on Friday, February 14th. The company reported ($0.09) earnings per share for the quarter.

Institutional Investors Weigh In On Citius Oncology

A hedge fund recently raised its stake in Citius Oncology stock. IFP Advisors Inc boosted its stake in shares of Citius Oncology, Inc. (NASDAQ:CTOR) by 173.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,215 shares of the company’s stock after purchasing an additional 14,080 shares during the period. IFP Advisors Inc’s holdings in Citius Oncology were worth $26,000 at the end of the most recent reporting period. 70.52% of the stock is currently owned by institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.